Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5

Biochemical Pharmacology

Volumn 82, Issue 6, 2011, Pages 681-691

  Kaspera, Rüdiger ^a   Naraharisetti, Suresh B ^a,d   Evangelista, Eric A ^a   Marciante, Kristin D ^b   Psaty, Bruce M ^a,b,c   Totah, Rheem A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amodiaquine; Cerivastatin; Ligand binding; Paclitaxel; Pharmacogenetics; Rosiglitazone

Indexed keywords

AMODIAQUINE; CERIVASTATIN; CYTOCHROME B5; CYTOCHROME P450 2C8; CYTOCHROME P450 REDUCTASE; DESMETHYLROSIGLITAZONE; FLUINDOSTATIN; HEME; PACLITAXEL; RECOMBINANT CYTOCHROME P450 2C8.1; RECOMBINANT CYTOCHROME P450 2C8.3; RECOMBINANT PROTEIN; ROSIGLITAZONE; TERFENADINE; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROSS COUPLING REACTION; DEETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOXICITY; ENZYME METABOLISM; ENZYME SPECIFICITY; ESCHERICHIA COLI; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LIVER MICROSOME; MOLECULAR PROBE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CYTOCHROMES B5; ESCHERICHIA COLI; HUMANS; KINETICS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PROTEIN BINDING; RATS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY;

EID: 80051544848     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.027     Document Type: Article

References (64)

1. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414 423 (Pubitemid 24229655)
2. S. Rendic, and F.J. Di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab Rev 29 1997 413 580 (Pubitemid 27293618)
3. R.A. Totah, and A.E. Rettie Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance Clin Pharmacol Ther 77 2005 341 352 (Pubitemid 40719263)
4. T. Karonen, A. Filppula, J. Laitila, M. Niemi, P.J. Neuvonen, and J.T. Backman Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast Clin Pharmacol Ther 88 2010 223 230
5. R. Kaspera, and R.A. Totah Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology Expert Opin Drug Metab Toxicol 5 2009 757 771
6. J.E. Thatcher, A. Zelter, and N. Isoherranen The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid Biochem Pharmacol 80 2010 903 912
7. D. Dai, D.C. Zeldin, J.A. Blaisdell, B. Chanas, S.J. Coulter, and B.I. Ghanayem Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 2001 597 607 (Pubitemid 32953585)
8. R. Kaspera, S.B. Naraharisetti, B. Tamraz, T. Sahele, M.J. Cheesman, and P.-Y. Kwok Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis Pharmacogen Genom 20 2010 619 629
9. E.B. Daily, and C.L. Aquilante Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies Pharmacogenomics 10 2009 1489 1510
10. S. Parikh, J.B. Ouedraogo, J.A. Goldstein, P.J. Rosenthal, and D.L. Kroetz Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa Clin Pharmacol Ther 82 2007 197 203 (Pubitemid 47075331)
11. Y. Gao, D. Liu, H. Wang, J. Zhu, and C. Chen Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions Xenobiotica 40 2010 467 475
12. A. Soyama, N. Hanioka, Y. Saito, N. Murayama, M. Ando, and S. Ozawa Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A Pharmacol Toxicol 91 2002 174 178 (Pubitemid 35216919)
13. H.E. Smith, J.P. Jones 3rd, T.F. Kalhorn, F.M. Farin, P.L. Stapleton, and C.L. Davis Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease Pharmacogenet Genomics 18 2008 943 953
14. S.E. Rowbotham, A.V. Boddy, C.P. Redfern, G.J. Veal, and A.K. Daly Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation Drug Metab Dispos 38 2010 1261 1266
15. A. Parikh, and F.P. Guengerich Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein Protein Expr Purif 9 1997 346 354 (Pubitemid 27210703)
16. H. Zhang, E. Myshkin, and L. Waskell Role of cytochrome b5 in catalysis by cytochrome P450 2B4 Biochem Biophys Res Commun 338 2005 499 506 (Pubitemid 41540596)
17. J.B. Schenkman, and I. Jansson The many roles of cytochrome b5 Pharmacol Ther 97 2003 139 152
18. F.P. Guengerich, M.V. Martin, P.H. Beaune, P. Kremers, T. Wolff, and D.J. Waxman Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism J Biol Chem 261 1986 5051 5060 (Pubitemid 17204301)
19. H. Zhang, S.C. Im, and L. Waskell Cytochrome b5 increases the rate of product formation by cytochrome P450 2B4 and competes with cytochrome P450 reductase for a binding site on cytochrome P450 2B4 J Biol Chem 282 2007 29766 29776 (Pubitemid 350035259)
20. P. Soucek Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies Arch Biochem Biophys 370 1999 190 200 (Pubitemid 29491424)
21. C.W. Locuson, P.M. Gannett, and T.S. Tracy Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9 Arch Biochem Biophys 449 2006 115 129
22. H. Yamazaki, M. Nakamura, T. Komatsu, K. Ohyama, N. Hatanaka, and S. Asahi Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli Protein Expr Purif 24 2002 329 337 (Pubitemid 35420057)
23. C.W. Locuson, L.C. Wienkers, J.P. Jones, and T.S. Tracy CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis Drug Metab Dispos 35 2007 1174 1181 (Pubitemid 46956439)
24. M. Niemi, J.B. Leathart, M. Neuvonen, J.T. Backman, A.K. Daly, and P.J. Neuvonen Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide Clin Pharmacol Ther 74 2003 380 387 (Pubitemid 37222859)
25. T.D. Porter, T.E. Wilson, and C.B. Kasper Expression of a functional 78 000 dalton mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, in Escherichia coli Arch Biochem Biophys 254 1987 353 367 (Pubitemid 17068827)
26. P.L. Holmans, M.S. Shet, C.A. Martin-Wixtrom, C.W. Fisher, and R.W. Estabrook The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function Arch Biochem Biophys 312 1994 554 565
27. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, and M.D. Provenzano Measurement of protein using bicinchoninic acid Anal Biochem 150 1985 76 85 (Pubitemid 16258399)
28. T. Omura, and R. Sato The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature J Biol Chem 239 1964 2370 2378
29. M.J. Cheesman, B.R. Baer, Y.M. Zheng, E.M. Gillam, and A.E. Rettie Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group Arch Biochem Biophys 416 2003 17 24 (Pubitemid 36818845)
30. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, and C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1997 1552 1562 (Pubitemid 28016533)
31. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
32. S.B. Naraharisetti, Y.S. Lin, M.J. Rieder, K.D. Marciante, B.M. Psaty, and K.E. Thummel Human liver expression of CYP2C8: gender, age, and genotype effects Drug Metab Dispos 38 2010 889 893
33. M. Nakano, E.J. Kelly, and A.E. Rettie Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase Drug Metab Dispos 37 2009 2119 2122
34. R.W. Kelley, J.R. Reed, and W.L. Backes Effects of ionic strength on the functional interactions between CYP2B4 and CYP1A2 Biochemistry 44 2005 2632 2641 (Pubitemid 40279567)
35. Y. Yasukochi, and B.S. Masters Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography J Biol Chem 251 1976 5337 5344
36. W. Huang, Y.S. Lin, D.J. McConn 2nd, J.C. Calamia, R.A. Totah, and N. Isoherranen Evidence of significant contribution from CYP3A5 to hepatic drug metabolism Drug Metab Dispos 32 2004 1434 1445 (Pubitemid 39564564)
37. L. Bordoli, F. Kiefer, K. Arnold, P. Benkert, J. Battey, and T. Schwede Protein structure homology modeling using SWISS-MODEL workspace Nat Protoc 4 2009 1 13
38. N.A. Baker, D. Sept, S. Joseph, M.J. Holst, and J.A. McCammon Electrostatics of nanosystems: application to microtubules and the ribosome Proc Natl Acad Sci U S A 98 2001 10037 10041 (Pubitemid 32802969)
39. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J Mol Graph 14 33-8 1996 27 28
40. P. Kuzmic Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase Anal Biochem 237 1996 260 273 (Pubitemid 26177089)
41. G.A. Schoch, J.K. Yano, S. Sansen, P.M. Dansette, C.D. Stout, and E.F. Johnson Determinants of cytochrome P450 2C8 substrate binding structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid J Biol Chem 283 2008 17227 17237
42. Y.S. Lin, A.L. Dowling, S.D. Quigley, F.M. Farin, J. Zhang, and J. Lamba Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 2002 162 172 (Pubitemid 34680528)
43. K. Venkatakrishnan, L.L. von Moltke, M.H. Court, J.S. Harmatz, C.L. Crespi, and D.J. Greenblatt Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches Drug Metab Dispos 28 2000 1493 1504
44. M.J. Cryle, and J.J. De Voss The role of the conserved threonine in P450 BM3 oxygen activation: substrate-determined hydroxylation activity of the Thr268Ala mutant Chembiochem 9 2008 261 266 (Pubitemid 351196794)
45. R.L. Walsky, and R.S. Obach Validated assays for human cytochrome P450 activities Drug Metab Dispos 32 2004 647 660 (Pubitemid 38668158)
46. S.J. Baldwin, S.E. Clarke, and R.J. Chenery Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone Br J Clin Pharmacol 48 1999 424 432 (Pubitemid 29417728)
47. L.A. McLaughlin, S. Ronseaux, R.D. Finn, C.J. Henderson, and C. Roland Wolf Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolism Mol Pharmacol 78 2010 269 278
48. R.D. Finn, L.A. McLaughlin, S. Ronseaux, I. Rosewell, J.B. Houston, and C.J. Henderson Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5 J Biol Chem 283 2008 31385 31393
49. D. Sandee, K. Morrissey, V. Agrawal, H.K. Tam, M.A. Kramer, and T.S. Tracy Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro Pharmacogenet Genomics 20 2010 677 686
50. V. Agrawal, N. Huang, and W.L. Miller Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19 Pharmacogenet Genomics 18 2008 569 576
51. J.R. Kurian, B.J. Longlais, and L.A. Trepanier Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity Pharmacogenet Genomics 17 2007 597 603 (Pubitemid 47057709)
52. L. Gan, L.L. von Moltke, L.A. Trepanier, J.S. Harmatz, D.J. Greenblatt, and M.H. Court Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes Drug Metab Dispos 37 2009 90 96
53. A. Bridges, L. Gruenke, Y.T. Chang, I.A. Vakser, G. Loew, and L. Waskell Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase J Biol Chem 273 1998 17036 17049 (Pubitemid 28311737)
54. N.N. Bumpus, and P.F. Hollenberg Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: identification of a potential site of interaction J Inorg Biochem 104 2010 485 488
55. D. Fishelovitch, S. Shaik, H.J. Wolfson, and R. Nussinov Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme: involvement of phenylalanine residues in the gating mechanism J Phys Chem B 113 2009 13018 13025
56. T.W. Ost, J. Clark, C.G. Mowat, C.S. Miles, M.D. Walkinshaw, and G.A. Reid Oxygen activation and electron transfer in flavocytochrome P450 BM3 J Am Chem Soc 125 2003 15010 15020 (Pubitemid 37509664)
57. F.P. Guengerich, and W.W. Johnson Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems Biochemistry 36 1997 14741 14750 (Pubitemid 27524395)
58. M.A. Noble, C.S. Miles, S.K. Chapman, D.A. Lysek, A.C. MacKay, and G.A. Reid Roles of key active-site residues in flavocytochrome P450 BM3 Biochem J 339 Pt 2 1999 371 379 (Pubitemid 29209968)
59. D.R. Davydov, and J.R. Halpert Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol 4 2008 1523 1535
60. W.M. Atkins Current views on the fundamental mechanisms of cytochrome P450 allosterism Expert Opin Drug Metab Toxicol 2 2006 573 579 (Pubitemid 46118327)
61. G. Hu, E.F. Johnson, and B. Kemper CYP2C8 exists as a dimer in natural membranes Drug Metab Dispos 38 2010 1976 1983
62. W.L. Backes, C.J. Batie, and G.F. Cawley Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4-1A2 complex with a high affinity for NADPH-cytochrome P450 reductase Biochemistry 37 1998 12852 12859 (Pubitemid 28433517)
63. W.L. Backes, and R.W. Kelley Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes Pharmacol Ther 98 2003 221 233 (Pubitemid 36513776)
64. A. Soyama, Y. Saito, N. Hanioka, N. Murayama, O. Nakajima, and N. Katori Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism Biol Pharm Bull 24 2001 1427 1430 (Pubitemid 33133761)